Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ammonium chloride | The serum concentration of Phenyl aminosalicylate can be increased when it is combined with Ammonium chloride. |
| Ginkgo biloba | The risk or severity of bleeding can be increased when Ginkgo biloba is combined with Phenyl aminosalicylate. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Phenyl aminosalicylate. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Phenyl aminosalicylate. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Phenyl aminosalicylate. |
| Methotrexate | The serum concentration of Methotrexate can be increased when it is combined with Phenyl aminosalicylate. |
| Pralatrexate | The serum concentration of Pralatrexate can be increased when it is combined with Phenyl aminosalicylate. |
| Probenecid | The therapeutic efficacy of Probenecid can be decreased when used in combination with Phenyl aminosalicylate. |
| Treprostinil | The risk or severity of bleeding can be increased when Treprostinil is combined with Phenyl aminosalicylate. |
| Ketoprofen | The risk or severity of bleeding and gastrointestinal bleeding can be increased when Phenyl aminosalicylate is combined with Ketoprofen. |
| Dexketoprofen | The risk or severity of bleeding and gastrointestinal bleeding can be increased when Phenyl aminosalicylate is combined with Dexketoprofen. |
| Coumarin | Phenyl aminosalicylate may increase the anticoagulant activities of Coumarin. |
| Digoxin | The serum concentration of Digoxin can be decreased when it is combined with Phenyl aminosalicylate. |
| Acetyldigitoxin | The serum concentration of Acetyldigitoxin can be decreased when it is combined with Phenyl aminosalicylate. |
| Deslanoside | The serum concentration of Deslanoside can be decreased when it is combined with Phenyl aminosalicylate. |
| Ouabain | The serum concentration of Ouabain can be decreased when it is combined with Phenyl aminosalicylate. |
| Digitoxin | The serum concentration of Digitoxin can be decreased when it is combined with Phenyl aminosalicylate. |
| Oleandrin | The serum concentration of Oleandrin can be decreased when it is combined with Phenyl aminosalicylate. |
| Cymarin | The serum concentration of Cymarin can be decreased when it is combined with Phenyl aminosalicylate. |
| Proscillaridin | The serum concentration of Proscillaridin can be decreased when it is combined with Phenyl aminosalicylate. |
| Metildigoxin | The serum concentration of Metildigoxin can be decreased when it is combined with Phenyl aminosalicylate. |
| Lanatoside C | The serum concentration of Lanatoside C can be decreased when it is combined with Phenyl aminosalicylate. |
| Gitoformate | The serum concentration of Gitoformate can be decreased when it is combined with Phenyl aminosalicylate. |
| Acetyldigoxin | The serum concentration of Acetyldigoxin can be decreased when it is combined with Phenyl aminosalicylate. |
| Peruvoside | The serum concentration of Peruvoside can be decreased when it is combined with Phenyl aminosalicylate. |
| Tioguanine | The metabolism of Tioguanine can be decreased when combined with Phenyl aminosalicylate. |
| Azathioprine | The metabolism of Azathioprine can be decreased when combined with Phenyl aminosalicylate. |
| Mercaptopurine | The metabolism of Mercaptopurine can be decreased when combined with Phenyl aminosalicylate. |
| Lepirudin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Lepirudin. |
| Bivalirudin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Bivalirudin. |
| Alteplase | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Alteplase. |
| Urokinase | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Urokinase. |
| Reteplase | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Reteplase. |
| Anistreplase | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Anistreplase. |
| Tenecteplase | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Tenecteplase. |
| Abciximab | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Abciximab. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Drotrecogin alfa. |
| Streptokinase | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Streptokinase. |
| Dicoumarol | Phenyl aminosalicylate may increase the anticoagulant activities of Dicoumarol. |
| Argatroban | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Argatroban. |
| Ardeparin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Ardeparin. |
| Phenindione | Phenyl aminosalicylate may increase the anticoagulant activities of Phenindione. |
| Fondaparinux | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Fondaparinux. |
| Warfarin | Phenyl aminosalicylate may increase the anticoagulant activities of Warfarin. |
| Pentosan polysulfate | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Pentosan polysulfate. |
| Phenprocoumon | Phenyl aminosalicylate may increase the anticoagulant activities of Phenprocoumon. |
| Dipyridamole | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Dipyridamole. |
| Heparin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Heparin. |
| Enoxaparin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Enoxaparin. |
| Epoprostenol | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Epoprostenol. |
| Acenocoumarol | Phenyl aminosalicylate may increase the anticoagulant activities of Acenocoumarol. |
| 4-hydroxycoumarin | Phenyl aminosalicylate may increase the anticoagulant activities of 4-hydroxycoumarin. |
| Ximelagatran | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Ximelagatran. |
| Desmoteplase | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Desmoteplase. |
| Defibrotide | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Defibrotide. |
| Ancrod | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Ancrod. |
| Beraprost | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Beraprost. |
| Prasugrel | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Prasugrel. |
| Rivaroxaban | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Rivaroxaban. |
| Sulodexide | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Sulodexide. |
| Semuloparin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Semuloparin. |
| Idraparinux | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Idraparinux. |
| Cangrelor | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Cangrelor. |
| Astaxanthin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Astaxanthin. |
| Apixaban | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Apixaban. |
| Otamixaban | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Otamixaban. |
| Amediplase | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Amediplase. |
| Dabigatran etexilate | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Dabigatran etexilate. |
| Danaparoid | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Danaparoid. |
| Dalteparin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Dalteparin. |
| Tinzaparin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Tinzaparin. |
| (R)-warfarin | Phenyl aminosalicylate may increase the anticoagulant activities of (R)-warfarin. |
| Ethyl biscoumacetate | Phenyl aminosalicylate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Nadroparin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Nadroparin. |
| Triflusal | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Triflusal. |
| Ticagrelor | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Ticagrelor. |
| Ditazole | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Ditazole. |
| Vorapaxar | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Vorapaxar. |
| Edoxaban | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Edoxaban. |
| Sodium citrate | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Sodium citrate. |
| Dextran | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Dextran. |
| Bemiparin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Bemiparin. |
| Parnaparin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Parnaparin. |
| Desirudin | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Desirudin. |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Antithrombin Alfa. |
| Protein C | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Protein C. |
| Antithrombin III human | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Antithrombin III human. |
| Letaxaban | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Letaxaban. |
| Darexaban | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Darexaban. |
| Betrixaban | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Betrixaban. |
| Nafamostat | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Nafamostat. |
| Monteplase | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Monteplase. |
| Gabexate | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Gabexate. |
| Fluindione | Phenyl aminosalicylate may increase the anticoagulant activities of Fluindione. |
| Protein S human | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Protein S human. |
| Brinase | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Brinase. |
| Clorindione | Phenyl aminosalicylate may increase the anticoagulant activities of Clorindione. |
| Diphenadione | Phenyl aminosalicylate may increase the anticoagulant activities of Diphenadione. |
| Tioclomarol | Phenyl aminosalicylate may increase the anticoagulant activities of Tioclomarol. |
| Melagatran | The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Melagatran. |